UBS Maintains Buy on ACADIA Pharmaceuticals, Lowers Price Target to $23
Portfolio Pulse from Benzinga Newsdesk
UBS analyst Ashwani Verma maintains a Buy rating on ACADIA Pharmaceuticals (NASDAQ:ACAD) but lowers the price target from $25 to $23.
August 08, 2024 | 1:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
UBS analyst Ashwani Verma maintains a Buy rating on ACADIA Pharmaceuticals but lowers the price target from $25 to $23.
The Buy rating suggests continued confidence in ACADIA Pharmaceuticals' prospects, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100